BACKGROUND:Protease inhibitor (PI)-based highly active antiretroviral therapy (HAART) use in pregnancy has been associated with preterm deliveries in some observational studies. METHODS:HIV-infected, HAART-naive pregnant women with CD4+ counts ≥200 cells/mm(3) were randomized between 26 and 34 weeks gestation to lopinavir/ritonavir/zidovudine/lamivudine (PI group) or abacavir/zidovudine/lamivudine (NRTI group) in a clinical trial to prevent mother-to-child HIV transmission. Risk factors for preterm delivery (<37 weeks) and differences by randomization arm were evaluated for live infants by logistic regression. RESULTS:Preterm delivery rates were higher among 267 women in the PI group than 263 women in the NRTI group (21.4% vs 11.8%, P = .003). PI-based HAART was the most significant risk factor for preterm delivery [odds ratio = 2.03, 95% confidence interval 1.26-3.27, P = .004]. Mean change in maternal body mass index (BMI) 1 month after HAART initiation was lower in the PI group (P < .001); however, this was not significantly associated with preterm delivery. Neither infant hospitalizations nor mortality through 6 months of life differed by maternal regimen. CONCLUSIONS:PI-based HAART was associated with increased preterm delivery but not increased infant hospitalizations or mortality in a clinical trial setting. The association between PI use and lower increase in BMI in late pregnancy warrants further study.
RCT Entities:
BACKGROUND:Protease inhibitor (PI)-based highly active antiretroviral therapy (HAART) use in pregnancy has been associated with preterm deliveries in some observational studies. METHODS:HIV-infected, HAART-naive pregnant women with CD4+ counts ≥200 cells/mm(3) were randomized between 26 and 34 weeks gestation to lopinavir/ritonavir/zidovudine/lamivudine (PI group) or abacavir/zidovudine/lamivudine (NRTI group) in a clinical trial to prevent mother-to-child HIV transmission. Risk factors for preterm delivery (<37 weeks) and differences by randomization arm were evaluated for live infants by logistic regression. RESULTS: Preterm delivery rates were higher among 267 women in the PI group than 263 women in the NRTI group (21.4% vs 11.8%, P = .003). PI-based HAART was the most significant risk factor for preterm delivery [odds ratio = 2.03, 95% confidence interval 1.26-3.27, P = .004]. Mean change in maternal body mass index (BMI) 1 month after HAART initiation was lower in the PI group (P < .001); however, this was not significantly associated with preterm delivery. Neither infant hospitalizations nor mortality through 6 months of life differed by maternal regimen. CONCLUSIONS: PI-based HAART was associated with increased preterm delivery but not increased infant hospitalizations or mortality in a clinical trial setting. The association between PI use and lower increase in BMI in late pregnancy warrants further study.
Authors: Edgardo G Szyld; Eduardo M Warley; Laura Freimanis; René Gonin; Pedro E Cahn; Guilherme A Calvet; Geraldo Duarte; Victor H Melo; Jennifer S Read Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: R L Shapiro; M D Hughes; A Ogwu; D Kitch; S Lockman; C Moffat; J Makhema; S Moyo; I Thior; K McIntosh; E van Widenfelt; J Leidner; K Powis; A Asmelash; E Tumbare; S Zwerski; U Sharma; E Handelsman; K Mburu; O Jayeoba; E Moko; S Souda; E Lubega; M Akhtar; C Wester; R Tuomola; W Snowden; M Martinez-Tristani; L Mazhani; M Essex Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: Kunjal Patel; David E Shapiro; Susan B Brogly; Elizabeth G Livingston; Alice M Stek; Arlene D Bardeguez; Ruth E Tuomala Journal: J Infect Dis Date: 2010-04-01 Impact factor: 5.226
Authors: Mary V Kinney; Kate J Kerber; Robert E Black; Barney Cohen; Francis Nkrumah; Hoosen Coovadia; Paul Michael Nampala; Joy E Lawn; Henrik Axelson; Anne-Marie Bergh; Mickey Chopra; Roseanne Diab; Ingrid Friberg; Oladoyin Odubanjo; Neff Walker; Eva Weissman Journal: PLoS Med Date: 2010-06-21 Impact factor: 11.069
Authors: Angela M Bengtson; Daniel Westreich; Patrick Musonda; Audrey Pettifor; Carla Chibwesha; Benjamin H Chi; Bellington Vwalika; Brian W Pence; Jeffrey S A Stringer; William C Miller Journal: Epidemiology Date: 2016-09 Impact factor: 4.822
Authors: Chloe R McDonald; Andrea L Conroy; Joel L Gamble; Eszter Papp; Michael Hawkes; Peter Olwoch; Paul Natureeba; Moses Kamya; Michael Silverman; Deborah Cohan; Catherine A Koss; Grant Dorsey; Kevin C Kain; Lena Serghides Journal: Clin Infect Dis Date: 2018-01-18 Impact factor: 9.079
Authors: Dorothy Sebikari; Mona Farhad; Terry Fenton; Maxensia Owor; Jeffrey S A Stringer; Min Qin; Nahida Chakhtoura; Benjamin H Chi; Friday Saidi; Neetal Nevrekar; Avy Violari; Tsungai Chipato; James A McIntyre; Dhayendre Moodley; Taha E Taha; Gerhard Theron; Mary Glenn Fowler Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731
Authors: Jennifer Y Chen; Heather J Ribaudo; Sajini Souda; Natasha Parekh; Anthony Ogwu; Shahin Lockman; Kathleen Powis; Scott Dryden-Peterson; Tracy Creek; William Jimbo; Tebogo Madidimalo; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226
Authors: Ellen C Caniglia; Rebecca Zash; Denise L Jacobson; Modiegi Diseko; Gloria Mayondi; Shahin Lockman; Jennifer Y Chen; Mompati Mmalane; Joseph Makhema; Miguel A Hernán; Roger L Shapiro Journal: AIDS Date: 2018-01-02 Impact factor: 4.177